Drug Profile
Lactitol - Sebela Pharmaceuticals
Alternative Names: BLI-400; BLI400 Laxative; PizensyLatest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Braintree Laboratories
- Class Osmotic laxatives; Small molecules; Sugar alcohols
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Constipation
Highest Development Phases
- Registered Constipation
Most Recent Events
- 12 Mar 2020 Chemical structure information added
- 04 Mar 2020 No development reported - Phase-II for Constipation (In adolescents) in USA (PO)
- 02 Mar 2020 Lactitol - Sebela Pharmaceuticals is available for licensing in USA as of 02 Mar 2020. www.sebelapharma.com 809286835